{
    "name": "teprotumumab",
    "comment": "Rx",
    "other_names": [
        "Tepezza",
        "teprotumumab-trbw"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Endocrine",
        "Insulinlike Growth Factor Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/tepezza-teprotumumab-4000026",
    "pregnancy": {
        "common": [
            "Based on findings in animals and its mechanism of action, fetal harm may occur when administered to a pregnant woman",
            "Adequate and well-controlled studies have not been conducted in pregnant women",
            "Data are insufficient with use in pregnant women to inform any drug-associated risks for adverse developmental outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In utero teprotumumab exposure in cynomolgus monkeys dosed once weekly with teprotumumab throughout pregnancy resulted in external and skeletal abnormalities",
                    "Teprotumumab exposure may lead to an increase in fetal loss; therefore, do not use during pregnancy",
                    "If patient becomes pregnant during treatment, discontinue treatment and advise patient of the potential risk to the fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to use effective contraception before initiation, during treatment, and for 6 months following the last dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding the presence of teprotumumab in human milk, the effects on the breastfed infant, or the effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Infusion reactions may occur; if an infusion reaction occurs, interrupt or slow infusion rate and use appropriate medical management",
                "May cause exacerbation of preexisting inflammatory bowel disease (IBD); monitor patients with preexisting IBD for flare of disease; discontinue treatment if IBD worsens",
                "Hyperglycemia reported; assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment; ensure patients with hyperglycemia or pre-existing diabetes are under appropriate glycemic control before and while receiving therapy"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Muscle spasms",
            "percent": "25"
        },
        {
            "name": "Nausea",
            "percent": "17"
        },
        {
            "name": "Alopecia",
            "percent": "13"
        },
        {
            "name": "Diarrhea",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "12"
        },
        {
            "name": "Hyperglycemia",
            "percent": "10"
        },
        {
            "name": "Hearing impairment",
            "percent": "10"
        },
        {
            "name": "Dysgeusia",
            "percent": "8"
        },
        {
            "name": "Headache",
            "percent": "8"
        },
        {
            "name": "Dry skin",
            "percent": "8"
        },
        {
            "name": "Exacerbation of preexisting inflammatory bowel disease",
            "percent": null
        },
        {
            "name": "Infusion reactions",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Diabetic ketoacidosis",
            "percent": null
        },
        {
            "name": "hyperosmolar hyperglycemic state",
            "percent": null
        },
        {
            "name": "HHS",
            "percent": null
        }
    ]
}